MIRLET7A2: MIRLET7A2 is a gene that is overexpressed in the PP adipose tissue of patients with prostate cancer (EPCa) [PMC3523039]. It is also overexpressed in the PP adipose tissue of obese/overweight (OB/OW) subjects with cancer compared to benign prostatic hyperplasia (BPH) [PMC3523039]. The MIRLET7A2 locus is located within a region that expresses several non-coding RNAs and is flanked by BORIS and CTCF binding sites [PMC5650274]. The MIRLET7A2 gene can be knocked out using sgRNAs and DICER plasmids [PMC9134915]. Chromosomal loss at 9q22 causes loss of the MIRLET7A gene family, including MIRLET7A2 [PMC7459851]. Methylation levels of CG dinucleotides in the promoter region of MIRLET7A2 can influence its expression [PMC9847511]. MIRLET7A2, along with other miRNA encoding genes, has low expression in murine eyes and is not expressed in ARPE-19 cell lines [PMC9847511]. The custom gene panel for mutation profiling includes MIRLET7A2 for pediatric cancers [PMC7341754]. Certain miRNAs, including MIRLET7A2, are suppressed upon differentiation [PMC4168020]. Deletion rates for MIRLET7A3 are higher than those for MIRLET7A2 and other genes within the let-7a cluster in certain cases [PMC5400605]. No significant differences were found for genotype and allele frequencies of SNPs located near miRNAs including MIRLET7A1 and MIRLET7A2 [PMC4650490].